Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 25,178,000	$ 60,795,000
General and administrative	26,012,000	29,523,000
Goodwill impairment charge	825,000	0
Total operating expenses	52,015,000	90,318,000
Loss from operations	(52,015,000)	(90,318,000)
Interest income	1,068,000	620,000
Other expense, net	(997,000)	(247,000)
Net loss before income tax benefit	(51,944,000)	0
Income tax benefit	284,000	0
Net loss	(51,660,000)	(89,945,000)
Other comprehensive income / (loss):
Foreign currency translation adjustments	248,000	20,000
Unrealized gain / (loss) on available for sales securities	(458,000)	(412,000)
Total comprehensive loss	$ (51,870,000)	$ (90,337,000)
Net loss per share - basic	$ (1.54)	$ (3.03)
Net loss per share - diluted	$ (1.54)	$ (3.03)
Weighted average shares of common stock outstanding - basic	33,496,534	29,718,506
Weighted average shares of common stock outstanding - diluted	33,496,534	29,718,506